Companies › DNLI

DENALI THERAPEUTICS INC (DNLI)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001714899 · EDGAR filings · Updated 2026-07-28

DENALI THERAPEUTICS INC (DNLI) has reported institutional ownership of 92.9%, with 266 institutional managers holding positions valued at $2.82B per the latest 13F reporting period.

Filings this week (1)

• 2026-07-28 — Current report (8-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-08 — SCHEDULE 13G/A filed
• 2026-06-18 — Current report (8-K) filed
• 2026-06-05 — Insider transaction reported (Form 4)
• 2026-06-05 — Insider transaction reported (Form 4)
• 2026-06-05 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, DENALI THERAPEUTICS INC has 266 institutional holders and institutional ownership of 92.9%.

Insider activity

Insiders reported 22 transactions (0 buys, 6 sells) across 13 reporting insiders, with a net reported value of −$8.39M.

Related companies

TRAVERE THERAPEUTICS INC (TVTX) · SUPERNUS PHARMACEUTICALS (SUPN) · VERACYTE INC (VCYT) · CARIS LIFE SCIENCES INC (CAI) · IMMUNOVANT INC (IMVT) · DISC MEDICINE INC (IRON)